Prediction of drug concentration-time data in humans from animals: a comparison of three methods

References

• Abadía AR, Aramayona JJ, Muñoz MJ, Pla Delfina JM, Saez MP, Bregante MA. (1994). Disposition of ciprofloxacin following intravenous administration in dogs. J Vet Pharmacol Ther 17:384–388.
   PubMed Web of Science ®Google Scholar
• Aramayona JJ, Mora J, Fraile LJ, García MA, Abadía AR, Bregante MA. (1996). Penetration of enrofloxacin and ciprofloxacin into breast milk, and pharmacokinetics of the drugs in lactating rabbits and neonatal offspring. Am J Vet Res 57:547–553.
   PubMed Web of Science ®Google Scholar
• Boxenbaum H. (1982). Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201–227.
   PubMedGoogle Scholar
• Boxenbaum H. (1984). Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev 15:1071–1121.
   PubMed Web of Science ®Google Scholar
• Boxenbaum H, Ronfeld R. (1983). Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 245:R768–R775.
   PubMed Web of Science ®Google Scholar
• Cook CS, Rozek LF, Stolzenbach J, Anderson S, Schoenhard GL, Karim A. (1993). Pharmacokinetics of a novel antiarrhythmic drug, actisomide. Pharm Res 10:427–433.
   PubMed Web of Science ®Google Scholar
• Dedrick R, Bischoff KB, Zaharko DS. (1970). Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 54:95–101.
   PubMedGoogle Scholar
• Duthu GS. (1985). Interspecies correlation of the pharmacokinetics of erythromycin, oleandomycin, and tylosin. J Pharm Sci 74:943–946.
   PubMed Web of Science ®Google Scholar
• Jones HM, Gardner IB, Collard WT, Stanley PJ, Oxley P, Hosea NA, Plowchalk D, Gernhardt S, Lin J, Dickins M, Rahavendran SR, Jones BC, Watson KJ, Pertinez H, Kumar V, Cole S. (2011). Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling. Clin Pharmacokinet 50:331–347.
   PubMed Web of Science ®Google Scholar
• Klotz U, Antonin KH, Bieck PR. (1976). Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. J Pharmacol Exp Ther 199:67–73.
   PubMed Web of Science ®Google Scholar
• Komiya M, Kikuchi Y, Tachibana A, Yano K. (1981). Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals. Antimicrob Agents Chemother 20:176–183.
   PubMedGoogle Scholar
• Lave T, Dupin S, Schmitt M, Kapps M, Meyer J, Morgenroth B, Chou RC, Jaeck D, Coassolo P. (1996). Interspecies scaling of tolcapone, a new inhibitor of catechol-O-methyltransferase (COMT). Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans. Xenobiotica 26:839–851.
   PubMed Web of Science ®Google Scholar
• Mahmood I. (1999). Prediction of clearance, volume of distribution and half-life by allometric scaling and by use of plasma concentrations predicted from pharmacokinetic constants: a comparative study. J Pharm Pharmacol 51:905–910.
   PubMedGoogle Scholar
• Mahmood I, Balian JD. (1996). Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887–895.
   PubMed Web of Science ®Google Scholar
• Mahmood I, Yuan R. (1999). A comparative study of allometric scaling with plasma concentrations predicted by species-invariant time methods. Biopharm Drug Dispos 20:137–144.
   PubMed Web of Science ®Google Scholar
• Matsui H, Yano K, Okuda T. (1982). Pharmacokinetics of the cephalosporin SM-1652 in mice, rats, rabbits, dogs, and rhesus monkeys. Antimicrob Agents Chemother 22:213–217.
   PubMedGoogle Scholar
• Mordenti J. (1985). Pharmacokinetic scale-up: accurate prediction of human pharmacokinetic profiles from animal data. J Pharm Sci 74:1097–1099.
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Koyama M, Matsui H, Ikeda C, Yano K, Nakatsuru N, Yoshinaga K, Noguchi T. (1984). Pharmacokinetics of cefpiramide (SM-1652) in humans. Antimicrob Agents Chemother 25:221–225.
   PubMedGoogle Scholar
• Nakagawa K, Koyama M, Tachibana A, Komiya M, Kikuchi Y, Yano K. (1982). Pharmacokinetics of cefotetan (YM09330) in humans. Antimicrob Agents Chemother 22:935–941.
   PubMedGoogle Scholar
• Saito A, Tomizawa M, Nakayama I, Sato K. (1988). Pharmacokinetics and clinical evaluation of cefodizime. Chemotherapy (Tokyo) 36(Suppl-5):281–293.
   Google Scholar
• Siefert HM, Maruhn D, Maul W, Förster D, Ritter W. (1986). Pharmacokinetics of ciprofloxacin. 1st communication: absorption, concentrations in plasma, metabolism and excretion after a single administration of [14C]ciprofloxacin in albino rats and rhesus monkeys. Arzneimittelforschung 36:1496–1502.
   PubMed Web of Science ®Google Scholar
• Sugeno K, Okabe H, Tanaka H, Norikura R. (1980). Disposition of 6059-S in rats, dogs and monkeys. Chemotherapy (Tokyo) 28(Suppl-7):207–218.
   Google Scholar
• Sukbuntherng J, Cropp G, Hannah A, Wagner GS, Shawver LK, Antonian L. (2001). Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416. J Pharm Pharmacol 53:1629–1636.
   PubMed Web of Science ®Google Scholar
• Swabb EA, Bonner DP. (1983). Prediction of aztreonam pharmacokinetics in humans based on data from animals. J Pharmacokinet Biopharm 11:215–223.
   PubMedGoogle Scholar
• Wajima T, Yano Y, Fukumura K, Oguma T. (2004). Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. J Pharm Sci 93:1890–1900.
   PubMed Web of Science ®Google Scholar
• Welling PG, Craig WA. (1978). Pharmacokinetics of intravenous erythromycin. J Pharm Sci 67:1057–1059.
   PubMed Web of Science ®Google Scholar
• Wise R, Lockley RM, Webberly M, Dent J. (1984). Pharmacokinetics of intravenously administered ciprofloxacin. Antimicrob Agents Chemother 26:208–210.
   PubMed Web of Science ®Google Scholar
• Yamada H, Yoshida T, Oguma T, Kimura Y, Tochino Y, Kurihara J, Matsumoto K, Uzuka Y, Shishido H, Nagatake T. (1980). Clinical pharmacology of 6059-S in healthy volunteers. Chemotherapy (Tokyo) 28(Suppl-7):251–262.
   Google Scholar
• Yamazaki S, Skaptason J, Romero D, Vekich S, Jones HM, Tan W, Wilner KD, Koudriakova T. (2011). Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model. Drug Metab Dispos 39:383–393.
   PubMed Web of Science ®Google Scholar